Trials / Completed

CompletedNCT00150735

Monotherapy With Levetiracetam in Newly Diagnosed Patients Suffering From Epilepsy

A Multicenter, Double-blind, Randomized, Parallel Group, Positive-controlled Trial Comparing the Efficacy and Safety of Levetiracetam (1000 to 3000 mg/Day Oral b.i.d.) to Carbamazepine (400 to 1200 mg/Day Oral b.i.d.), Used as Monotherapy for up to a Maximum of 121 Weeks in Subjects (≥ 16 Years) Newly or Recently Diagnosed as Suffering From Epilepsy, and Experiencing Partial or Generalized Tonic-clonic Seizures

Status: Completed
Phase: Phase 3
Study type: Interventional
Enrollment: 580 (planned)

Sponsor: UCB Pharma · Industry
Sex: All
Age: 16 Years
Healthy volunteers: —

Summary

A double-blind trial comparing the efficacy and safety of levetiracetam to carbamazepine used as monotherapy in subjects (≥ 16 years) newly or recently diagnosed as suffering from epilepsy, and experiencing partial or generalized tonic-clonic seizures.

Conditions

Generalized Epilepsy

Interventions

Type	Name	Description
DRUG	LEVETIRACETAM

Timeline

Start date: 2002-06-01
Primary completion: 2005-07-01
Completion: 2005-07-01
First posted: 2005-09-08
Last updated: 2013-11-26

Source: ClinicalTrials.gov record NCT00150735. Inclusion in this directory is not an endorsement.